MTA was introduced in 1993 and approved by the FDA in 1998. It exhibits good biocompatibility, sealing ability, and tissue regeneration. MTA is available as grey or white powders mixed with water. It has a high pH and compressive strength increases over time. MTA has applications in pulp capping and non-vital pulpotomies due to its biocompatibility and ability to stimulate hard tissue formation and repair.
Mineral Trioxide Aggregate (MTA) is identical to Portland cement. It is a new remarkable biocompatible material with exciting clinical applications pioneered by Dr. Mahmoud Torabinejad, Loma Linda University, in 1993
Mineral trioxide aggregate/ orthodontic courses by indian dental academyIndian dental academy
Indian Dental Academy: will be one of the most relevant and exciting training center with best faculty and flexible training programs for dental professionals who wish to advance in their dental practice,Offers certified courses in Dental implants,Orthodontics,Endodontics,Cosmetic Dentistry, Prosthetic Dentistry, Periodontics and General Dentistry.
MTA uses, MTA types, Mineral Trioxide Aggregate, why we use mta not Portland cement, MTA Mixing, mta carrier, block matrix mta, mta map system, usage of MTA, pulp capping , pulptomy, apexification, regenerative endodontics, revitalization, revasclarization, internal & external root resorption, obturation, root perforation, root end filling, biodentine, MTA Fillapex, MM-MTA, THERACAL LC, Endosequence selar
Mineral Trioxide Aggregate (MTA) is identical to Portland cement. It is a new remarkable biocompatible material with exciting clinical applications pioneered by Dr. Mahmoud Torabinejad, Loma Linda University, in 1993
Mineral trioxide aggregate/ orthodontic courses by indian dental academyIndian dental academy
Indian Dental Academy: will be one of the most relevant and exciting training center with best faculty and flexible training programs for dental professionals who wish to advance in their dental practice,Offers certified courses in Dental implants,Orthodontics,Endodontics,Cosmetic Dentistry, Prosthetic Dentistry, Periodontics and General Dentistry.
MTA uses, MTA types, Mineral Trioxide Aggregate, why we use mta not Portland cement, MTA Mixing, mta carrier, block matrix mta, mta map system, usage of MTA, pulp capping , pulptomy, apexification, regenerative endodontics, revitalization, revasclarization, internal & external root resorption, obturation, root perforation, root end filling, biodentine, MTA Fillapex, MM-MTA, THERACAL LC, Endosequence selar
Root repair materials in Dentistry is evolving like never before with the advent of bioactive materials.lets have quick look at the products that have become history to the recent advances .
Bioceramics are materials which include Alumina, Zirconia, Bioactive glass, Glass ceramics, Hydroxyapatite, resorbable Calcium phosphates.
Used in dentistry for
Filling up bony defects
Root repair materials
Apical fill materials
Aids in regeneration etc.
Bioinert: non-interactive with biological systems (Alumina, zirconia)
Bioactive: durable tissues that can undergo interfacial interactions with surrounding tissue (bioactive glasses, bioactive glass ceramics, hydroxyapatite, calcium silicates)
Biodegradable: soluble or resorbable, eventually replaced or incorporated into tissue (Tricalcium phosphate, Bioactive glasses).
Mineral trioxide aggregate, described in 1993, is an aggregate of mineral oxides added to “trioxides” of tricalcium silicate, tricalcium aluminate, and tricalcium oxide silicate oxide.
It was patented by Mahmoud Torabinejad and Dean White, and described it as the tooth filling material comprising of Portland cement ( TYPE 1)
hydraulic type of cement
Biodentine, a tricalcium silicate based dental material was introduced by Septodont in the year 2010known as “dentine in a capsule”
The product was synthesized de novo and was free from the impurities present in the derivatives of portland cement like MTA.
It helps in achieving biomimetic mineralisation within the depths of a carious cavity
The permanent teeth with open apex and large periapical lesion are diffcult to treat as a traditional root canal procedure, therefore calcium hydroxide place an important role in reducing the periapical infl ammation. Management of open apex can be done using mineral trioxide aggregate (MTA) which can be placed in apical 3-4 mm. The aim of this This case report describes the use of mineral trioxide aggregate (MTA) for management of a periapically compromised immature tooth.
Indian Dental Academy: will be one of the most relevant and exciting training center with best faculty and flexible training programs for dental professionals who wish to advance in their dental practice,Offers certified courses in Dental implants,Orthodontics,Endodontics,Cosmetic Dentistry, Prosthetic Dentistry, Periodontics and General Dentistry.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Root repair materials in Dentistry is evolving like never before with the advent of bioactive materials.lets have quick look at the products that have become history to the recent advances .
Bioceramics are materials which include Alumina, Zirconia, Bioactive glass, Glass ceramics, Hydroxyapatite, resorbable Calcium phosphates.
Used in dentistry for
Filling up bony defects
Root repair materials
Apical fill materials
Aids in regeneration etc.
Bioinert: non-interactive with biological systems (Alumina, zirconia)
Bioactive: durable tissues that can undergo interfacial interactions with surrounding tissue (bioactive glasses, bioactive glass ceramics, hydroxyapatite, calcium silicates)
Biodegradable: soluble or resorbable, eventually replaced or incorporated into tissue (Tricalcium phosphate, Bioactive glasses).
Mineral trioxide aggregate, described in 1993, is an aggregate of mineral oxides added to “trioxides” of tricalcium silicate, tricalcium aluminate, and tricalcium oxide silicate oxide.
It was patented by Mahmoud Torabinejad and Dean White, and described it as the tooth filling material comprising of Portland cement ( TYPE 1)
hydraulic type of cement
Biodentine, a tricalcium silicate based dental material was introduced by Septodont in the year 2010known as “dentine in a capsule”
The product was synthesized de novo and was free from the impurities present in the derivatives of portland cement like MTA.
It helps in achieving biomimetic mineralisation within the depths of a carious cavity
The permanent teeth with open apex and large periapical lesion are diffcult to treat as a traditional root canal procedure, therefore calcium hydroxide place an important role in reducing the periapical infl ammation. Management of open apex can be done using mineral trioxide aggregate (MTA) which can be placed in apical 3-4 mm. The aim of this This case report describes the use of mineral trioxide aggregate (MTA) for management of a periapically compromised immature tooth.
Indian Dental Academy: will be one of the most relevant and exciting training center with best faculty and flexible training programs for dental professionals who wish to advance in their dental practice,Offers certified courses in Dental implants,Orthodontics,Endodontics,Cosmetic Dentistry, Prosthetic Dentistry, Periodontics and General Dentistry.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
2. Mineral Trioxide Aggregate (MTA), which was
introduced by Dr. Mahmoud Torabinejad at Loma Linda
University, California, US and the first literature about the
material appeared in 1993. MTA was originally formulated
to provide the physical properties, setting requirements
and characteristics necessary for an ideal repair and
medicament material.
Studies reveal that MTA exhibits good sealing ability,
excellent long term prognosis, good biocompatibility and
tissue regeneration.
MTA has been approved by the U.S. Food and Drug
Administration (FDA) in the year 1998. With its numerous
exciting clinical applications, MTA promises to be one of
the most versatile materials of this century in the field of
dentistry.
3. Availability of MTA
Mineral trioxide aggregate (MTA) is a fine hydrophilic powder, available in
single use sachets of 1 gram. Some companies also provide
premeasured water sachets for ease of use.
4. Composition
MTA is a mechanical mixture of 3 powder ingredients:
Portland cement (75%), Bismuth oxide (20%), Gypsum (5%).
Its composition is said to be similar to Portland cement
except for the absence of bismuth oxide in Portland
cement. The MTA particles are smaller and uniform in size
whereas the particle size of Portland cement vary in size.
Bismuth oxide is added to improve the properties and the
radioopacity.
The composition of MTA includes :
Tricalcium silicate, Di Calcium silicate, Tricalcium aluminate,
Tricalcium oxide, Silicate oxide, Bismuth oxide.
5. MTA is available in two types based on the color known as
Grey and White MTA.
Grey MTA White MTA
Contains tetracalcium
aluminoferrite (Ferrous oxide)
which is responsible for gray
discoloration. So, it can cause
discoloration of teeth, so that it
not used with anterior teeth.
Ferrous oxide is replaced by
Magnesium oxide, so no tooth
discoloration.
Large particles. Smaller particles with narrower
size distribution.
Longer setting time. Shorter.
Greater compressive strength. Less.
Types of MTA
6. Manipulation and setting reaction of MTA
The MTA paste is obtained by mixing 3 parts of powder
with 1 part of water to obtain putty like consistency.
Mixing can be done on paper or on a glass slab using a
plastic or metal spatula. This mix is then placed in the
desired location and condensed lightly with a moistened
cotton pellet.
MTA has a pH of 10.2 immediately after mixing and
increases to 12.5 after 4 hours of setting which is almost
similar to calcium hydroxide.
MTA powder should be stored carefully in closed sealed
containers away from moisture. The mixing time of MTA is
crucial. If the mixing of MTA is prolonged, it results in
dehydration of the mix. The manipulation time should be
less than 4 minutes.
7. Extended setting period of MTA is one of its main drawbacks.
It is suggested by many investigators that the incorporation
of accelerators such as sodium phosphate dibasic
(Na2HPO4) and calcium chloride (CaCl2) may reduce the
setting time.
MTA being hydrophilic requires moisture to set, making
absolute dryness contraindicated. Presence of moisture
during setting improves the flexural strength of the set
cement.
Hydration of the powder results in a colloidal gel composed
of calcium oxide crystals in an amorphous structure (33%
calcium, 49% phosphate, 6% silica, 3% chloride and
2% carbon).
8. After mixing, the mix should not be left open on the slab as
it undergoes dehydration
and dries into a sandy mixture. It should be used
immediately after it is prepared.
MTA may be placed into the desired location using hand
instruments (not condensed with excess pressure). Hand
condensation is done with the help of a plugger or messing
gun.
Increase in condensation pressure might reduce the surface
hardness. The explanation was that increasing the
condensation pressure probably reduces the space
required for the ingress of water which is required to
hydrate the cement.
9.
10.
11. Properties of MTA
1. Compressive strength:
• It takes an average of 3-4 hours for the MTA material to completely
solidify. It has been shown that once it is set, it has a compressive
strength equal to IRM and Super EBA but less than amalgam.
• Compressive strength of MTA within 24 hours of mixing was about
40.0 MPa and increases to 67.3 MPa after 21 days.
• In comparison grey MTA exhibited greater compressive strength
than white MTA.
2. PH:
• MTA has an initial pH of 10.2 that rises to 12.5 three hours after
mixing .
12. 3. Radio-opacity:
• MTA is less radio opaque than IRM, Super EBA , amalgam or gutta-
percha and has similar radiodensity as Zinc Oxide Eugenol.
• The mean radio opacity of MTA is 7.17 mm of equivalent thickness
of aluminium, which is sufficient to make it easy to visualize
radiographically.
4. Solubility:
• Although the set MTA shows no signs of solubility, the solubility
might increase if more water is used during mixing.
• The set MTA when exposed to water releases calcium hydroxide
which might be responsible for its cementogenesis inducing
property.
13. 5. Marginal adaptation and sealing ability:
• MTA expands during setting which may be the reason for its excellent
sealing ability. MTA thickness of about 4mm is sufficient to provide a good.
• According to Torabinejad et al in 1995 MTA seals very superiorly and no
gaps were found in any of the experimental specimen.
6. Antibacterial and antifungal property:
• The MTA cements have antibacterial and fungicidal properties (because of
high pH) in relation to following types:
Enterococcus faecalis.
Streptococcus sanguis.
Staphylococcus epidermis.
Micrococcus luteus.
Pseudomonas aeruginosa.
Escherichia coli.
Candia albicans.
14. • MTA found that it is not mutagenic and is much less cytotoxic
compared to Super EBA and IRM. This supports the superiority of
MTA over formocresol as a pulpotomy medicament.
• Genotoxicity tests of cells after treatment of peripheral lymphocytes
with MTA showed no DNA damage. On direct contact they produce
minimal or no inflammatory reaction in soft tissues and in fact are
capable of inducing tissue regeneration.
• Arens and Torabinejad in 1996 reported osseous repair of furcation
perforations treated with MTA. MTA showed good interaction with
bone-forming cells (cells remained viable and released collagen
even after 72 hours with good adherence).
7. Biocompatibility:
15. 8. Reaction with other dental materials:
• MTA does not react or interfere with any other restorative material.
Glass Ionomer cements or composite resins, used as permanent
filling material do not affect the setting of MTA when placed over it.
• Possible interactions might occur when MTA cement is combined
with other materials during the endodontic treatment:
Chlorhexidine (CHX): might cause difficulties for correct setting.
Sodium hypochlorite (NaOCl): might cause a shorter time of
setting,.
Saline (NaCl): might cause a longer time of setting,
Lignocaine: might cause a longer time of setting.
9. Tissue regeneration:
• MTA is capable of activation of cementoblasts and production of
cementum. It consistently allows for the overgrowth of cementum
and also facilitates regeneration of the periodontal ligament. MTA
allows bone healing and eliminates clinical symptoms in many cases.
16. • MTA, just like calcium hydroxide, induces dentin bridge
formation. Many investigators believe that the hard tissue
bridge deposited next to MTA is because of the sealing
property, biocompatibility, alkalinity and other properties
associated with this material.
• The tricalcium oxide in MTA reacts with tissue fluids to
form calcium hydroxide, resulting in hard-tissue formation
in a manner similar to that of calcium hydroxide. But the
dentin bridge that is formed with MTA is faster, with good
structural integrity and more complete than with calcium
hydroxide. MTA also proves to be better at stimulating
reparative dentin formation and maintaining the
integrity of the pulp.
10. Mineralization:
17. Property Ca(OH)2 MTA
Hard tissue formation Not much Root end induction
Calcific bridge Not continuous
slow
Continuous with dentin
fast
Biocompatibility Low High
Degree of inflammation High Low
Sets Not Hard Hard
pH High High
Solubility Partially dissolve Less soluble
Permeability Permeable to fluids Non permeable
Resorption Rate vary with density Non-resorbable
Appical closure Unpredictability Good
MTA versus Ca(OH)2
19. 1. Pulp Capping:
• MTA has been proposed as a potential medicament for capping of pulps
with reversible pulpitis because of its excellent tissue compatibility. It is
much superior to the routinely used calcium hydroxide based on the tissue
reaction and the amount and type of dentin bridge formed.
• Calcium hydroxide is associated with tissue necrosis and inflammation
during the initial period of placement but no such inflammation or
necrosis was seen in the pulp tissue adjacent to MTA.
• With MTA, dentin bridge after pulp capping was seen at about 1 week
which steadily increased in length and thickness within 3 months of
capping whereas following pulp capping with calcium hydroxide, the dentin
bridge was less consistent and had numerous tunnel defects.
• Since there is no pulpal necrosis, pulp tissue heals faster with MTA.
Aeinehchi et al in 2003 reported a 0.28 mm thick dentin bridge by 2
months which increased to 0.43 mm by 6 months. The dentin bridge
formed with calcium hydroxide was only 0.15 mm by 6 months.
20.
21. 2. Non vital pulpotomy:
• Formacresol has been routinely used as a pulpotomy agent for deciduous teeth.
But this material has been criticized for its tissue irritating, cytotoxic and
mutagenic effects.
• MTA was tested and found to be an ideal material with low toxic effects, increased
tissue regenerating properties and good clinical results.
• Furthermore, the presence of blood has little impact on the setting or degree of
leakage when a 2-millimeter-thick layer of MTA was placed over the pulp during
pulpotomy.
• Discoloration of teeth was observed in
60% of the deciduous molars treated
with MTA. But this was not of
significance since the tooth was later
restored with a stainless steel crown.
22. 3. Vital pulpotomy (Apexogenesis):
• Apexogenesis is defined as amputation of coronal pulp completely
without inserting any thing into root canal system. This procedure was
used for vital teeth with immature roots.
23. • Bleeding is controlled with a cotton moistened with Sodium
Hypochlorite (NaOCl).
• MTA is placed over the exposed pulp using a large amalgam carrier.
• The material is padded into place with a moist cotton pellet.
• The moist cotton pellet is placed on the MTA and the material is
allowed to set. The rest of the cavity is filled with temporary filling
material.
• In the next visit the temporary material is removed along with the
cotton pellet and the tooth is restored with a permanent restoration.
• The entire cavity can also be filled with MTA, instead of temporary
material. A wet piece of gauze is placed between the treated tooth and
the opposing tooth for 3-4 hours. This can be done only in compliant
patients.
• After 1 week, about 3-4 mm of the material from the occlusal surface is
removed and final restoration placed over the set MTA.
Steps involved in the placement of a pulp capping, pulpotomy
24. 4. Root-end filling:
• Endodontic surgery followed by root-end filling may at times be
necessary for certain teeth where routine endodontic treatment is not
possible. This procedure involves surgical exposure of the root apex,
root resection and plugging the apical foramen with a suitable material
that provides complete apical seal, is non toxic, non resorbable,
dimensionally stable and radio opaque.
• Many materials have been used as root-end filling agents but the main
disadvantage is their failure to prevent leakage and the lack of
biocompatibility.
• Amalgam, although routinely used as a root-end filling material, proved
to be much inferior when tested with MTA. MTA treated teeth exhibited
significantly less inflammation, more cementum formation and
regeneration of periradicular tissues.
25. • Flap is raised under local anesthesia. This is followed by ostectomy,
root-end resection and hemorrhage control.
• MTA is placed into the prepared root end cavity with a small carrier
and mildly patted into place with a plugger.
• Since placement of wet cotton over the setting MTA is not possible,
moist environment can be created by inducing mild bleeding from
adjacent tissues and bringing the blood over the MTA.
• The area should not be rinsed after the placement of MTA.
• Flap is then sutured back into place.
Steps involved in root-end filling
26.
27. 5. Apical plug (Apexification of non vital of immature roots):
• Conventional management of an immature non vital permanent tooth
is apexification with calcium hydroxide.
• The purpose of apexification is to obtain an apical barrier so as to
prevent the extrusion of the obturating material.
• But the disadvantage of using calcium hydroxide is the extended time
taken for the completion of the procedure which may range anywhere
between 3 to 54 months.
• The tooth with calcium hydroxide placed for more than 100 days
showed a significant reduction in fracture resistance.
• This problem is solved with the use of MTA. An MTA plug of 4mm
thickness placed at the apical region is adequate to form a barrier,
sealing the canal from the periapical area.
28. • Access opening is done under local anesthesia and rubber dam.
• The root canal is cleaned with intracanal irrigants.
• Calcium hydroxide paste can be placed in the canal to disinfect for
about 1 week.
• Calcium hydroxide is removed by rinsing. Excess moisture is removed
from the canal.
• Mixed MTA is placed in the cavity using a large amalgam carrier. The
material is pushed towards the apical foramen with a plugger or paper
points.
• The apical plug should be at least 3 to 4 mm thick and this should be
checked radiographically.
• If the apical plug could not be placed adequately, the entire material is
rinsed from the canal with sterile water and the procedure repeated.
• A moist cotton pellet is placed in the canal and the tooth is temporarily
restored.
• After 3 hours, the remaining canal is obturated with gutta percha and a
permanent restoration is then placed.
Steps involved in apical plug placement
29.
30. 6. Obturation of the canal:
• Mineral Trioxide Aggregate can be used to obturate the root canal of a
retained primary tooth where the succedaneous permanent tooth is
absent.
• This technique is not recommended for obturation of primary teeth
that are expected to exfoliate since it is anticipated that Mineral
Trioxide Aggregate would be absorbed slowly, if at all.
7. Repair of perforation:
• Repairing requires a material that should be biocompatible, should
withstand moisture without dissolving and should have good sealing
ability.
• MTA was used for treatment of perforation that caused by an iatrogenic
causes or complication of internal resorption.
31. • Procedure is done under anesthesia and rubber dam.
• After performing access opening, the canals are irrigated with NaOCl.
• Calcium hydroxide can be placed in the canal in between appointments
which will help control hemorrhage.
• Before placing MTA, calcium hydroxide should be completely removed.
• The apical portion of the canal is obturated with sectional cone
technique using gutta percha and root canal sealer.
• MTA is placed into the defect and moist cotton pellet is placed over it.
The access cavity is closed with a temporary restoration.
• The remaining portion of the canal is restored with a permanent filling
material after at least 3-4 hours.
Steps involved in the repair of perforation:
32.
33. 8. Repair of fracture:
• The success rate of horizontal root fracture treatment depending on their
location (cervical, middle, and apical). The root fracture located in the
cervical and middle thirds causes difficulty for treatment because it is
difficult for dental immobilization, leading to injury or even preventing the
consolidation of the fragments.
• For these cases, it is possible to strengthen the tooth with an intra-canal
pin cemented with MTA
• The canal is instrumented, and then an apical plug with MTA is performed.
A metal pin is selected in order to remain adjusted in the canal, which is
filled with MTA, seating the pin inside. Thus, there is reinforcement for the
root, preventing mobility of the coronary segment.
A. Horizontal root fracture:
34.
35. • Vertical fracture has a very poor prognosis.
• To repair a vertical fracture, remove the root canal filling material from
the treated root(s) and bond the pieces internally with composite
bonded resin.
• After raising a flap, groove the entire vertical fracture to the composite
with a small bur under constant water spray. Place MTA in the groove,
cover it with a resorbable membrane, and suture the soft tissue flap.
• They have also suggested that the tooth can be intentionally extracted
to repair the fracture if the fracture line cannot be assessed by flap
surgery followed by reimplanting it back into the socket.
• To improve the prognosis of these cases, the patients should be
instructed to follow meticulous oral hygiene and the treated tooth
should not be probed for at least 12 wk.
B. Vertical root fracture:
36. References
• Rao A, Rao A, Shenoy R. Mineral trioxide aggregate-A review. J Clin Pediatr Dent. 2009;
34(1):1-8.
• Srinivasan V, Waterhouse P, Whitworth J. Mineral trioxide aggregate in paediatric dentistry.
International Journal of Paediatric Dentistry. 2009; 19:34-47.
• Macwan C, Deshpande A. Mineral trioxide aggregate (MTA) in dentistry: A review of
literature. Journal of Oral Research and Review. 2014; 6(2):71-74.
• Simon S, Rilliard F, Berdal A, Machtou P. The use of mineral trioxide aggregate in one-visit
apexification treatment: a prospective study. International Endodontic Journal. 2007;
40:186-197.
• Hegde R, Battepat PM. Clinical Applications of Mineral Trioxide Aggregate: report of four
cases. International Journal of Clinical Pediatric Dentistry, January. 2010; 3(1):43-50.
• Castellucci A. The use of mineral trioxide aggregate in clinical and surgical endodontics.
Dent Today. 2003; 22(3):74-81.
• Camilleri J. Mineral Trioxide Aggregate in Dentistry: From preparation to application. 1st
ed. 2014; Springer Heidelberg New York Dordrecht London.